Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

An Ω-3 fatty acid desaturase-expressing gene attenuates prostate cancer proliferation by cell cycle regulation.

Pan J, Zhou S, Xiang R, Zhao Z, Liu S, Ding N, Gong S, Lin Y, Li X, Bai X, Li F, Zhao AZ.

Oncol Lett. 2017 May;13(5):3717-3721. doi: 10.3892/ol.2017.5880. Epub 2017 Mar 21.

2.

Mucosal Interactions between Genetics, Diet, and Microbiome in Inflammatory Bowel Disease.

Basson A, Trotter A, Rodriguez-Palacios A, Cominelli F.

Front Immunol. 2016 Aug 2;7:290. doi: 10.3389/fimmu.2016.00290. eCollection 2016. Review.

3.

n-3 Polyunsaturated Fatty Acids and their Role in Cancer Chemoprevention.

Gu Z, Shan K, Chen H, Chen YQ.

Curr Pharmacol Rep. 2015 Oct;1(5):283-294. Epub 2015 Jul 5.

4.

Targeting of cytosolic phospholipase A2α impedes cell cycle re-entry of quiescent prostate cancer cells.

Yao M, Xie C, Kiang MY, Teng Y, Harman D, Tiffen J, Wang Q, Sved P, Bao S, Witting P, Holst J, Dong Q.

Oncotarget. 2015 Oct 27;6(33):34458-74. doi: 10.18632/oncotarget.5277.

5.

The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment.

Dueregger A, Heidegger I, Ofer P, Perktold B, Ramoner R, Klocker H, Eder IE.

Nutrients. 2014 Oct 21;6(10):4491-519. doi: 10.3390/nu6104491. Review.

6.

Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A₂α via AKT in prostate cancer cells.

Vignarajan S, Xie C, Yao M, Sun Y, Simanainen U, Sved P, Liu T, Dong Q.

Oncotarget. 2014 Aug 15;5(15):6289-99.

7.

Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells.

Huang EC, Zhao Y, Chen G, Baek SJ, McEntee MF, Minkin S, Biggerstaff JP, Whelan J.

BMC Complement Altern Med. 2014 Feb 21;14:68. doi: 10.1186/1472-6882-14-68.

8.

15-Lipoxygenase-1-mediated metabolism of docosahexaenoic acid is required for syndecan-1 signaling and apoptosis in prostate cancer cells.

Hu Y, Sun H, O'Flaherty JT, Edwards IJ.

Carcinogenesis. 2013 Jan;34(1):176-82. doi: 10.1093/carcin/bgs324. Epub 2012 Oct 11.

9.

Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.

Wang S, Wu J, Suburu J, Gu Z, Cai J, Axanova LS, Cramer SD, Thomas MJ, Perry DL, Edwards IJ, Mucci LA, Sinnott JA, Loda MF, Sui G, Berquin IM, Chen YQ.

Carcinogenesis. 2012 Feb;33(2):404-12. doi: 10.1093/carcin/bgr290. Epub 2011 Dec 8.

10.

Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer.

Reese AC, Fradet V, Witte JS.

J Nutrigenet Nutrigenomics. 2009;2(3):149-58. doi: 10.1159/000235565. Epub 2009 Sep 23. Review.

11.

Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk.

Fradet V, Cheng I, Casey G, Witte JS.

Clin Cancer Res. 2009 Apr 1;15(7):2559-66. doi: 10.1158/1078-0432.CCR-08-2503. Epub 2009 Mar 24.

12.

A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality.

Chavarro JE, Stampfer MJ, Hall MN, Sesso HD, Ma J.

Am J Clin Nutr. 2008 Nov;88(5):1297-303.

Supplemental Content

Support Center